Sign inCreate account

Report workspace tools

NCT05654623ACTIVE_NOT_RECRUITINGanonymous

A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)

Sponsor

Source record

Pfizer

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Estrogen Receptor (ER) degradation via PROTAC mechanism (specifically targeting ER+ breast cancer).

Indication / condition

AI-normalized

Advanced Breast Cancer

Intervention

Source record

ARV-471, Fulvestrant

Source & freshness

Source record

NCT ID

NCT05654623

Original source

ClinicalTrials.gov

Source last updated

Mar 18, 2026

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05654623

Title

A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)

Sponsor

Pfizer

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 3

Condition raw

Advanced Breast Cancer

Condition normalized

Advanced Breast Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Estrogen Receptor (ER) degradation via PROTAC mechanism (specifically targeting ER+ breast cancer).

Target normalized

Estrogen Receptor (ER) degradation via PROTAC mechanism (specifically targeting ER+ breast cancer).

Interventions

ARV-471, Fulvestrant

Public preview

Source record

ARV-471 (PF-07850327) is being evaluated against fulvestrant in a pivotal Phase 3 trial for ER+/HER2- advanced breast cancer patients who have progressed after prior endocrine therapy. The market for advanced breast cancer treatments is significant, with a growing demand for novel therapies that can overcome resistance to existing treatments. If successful, ARV-471 could capture a substantial share of the market, particularly given the limitations of current therapies like fulvestrant. Competitive implications include positioning against other SERDs and emerging therapies targeting similar patient populations. Diligence should focus on the trial's primary and secondary endpoints, safety profile, and potential market entry timelines.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05654623

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 3

Sponsor

Pfizer

Executive brief

Investment-Ready Snapshot

ARV-471 (PF-07850327) is being evaluated against fulvestrant in a pivotal Phase 3 trial for ER+/HER2- advanced breast cancer patients who have progressed after prior endocrine therapy. The market for advanced breast cancer treatments is significant, with a growing demand for novel therapies that can overcome resistance to existing treatments. If successful, ARV-471 could capture a substantial share of the market, particularly given the limitations of current therapies like fulvestrant. Competitive implications include positioning against other SERDs and emerging therapies targeting similar patient populations. Diligence should focus on the trial's primary and secondary endpoints, safety profile, and potential market entry timelines.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 18, 2026
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05654623

Indication

Advanced Breast Cancer

Modality

small molecule

Target

Estrogen Receptor (ER) degradation via PROTAC mechanism (specifically targeting ER+ breast cancer).

Intervention

ARV-471, Fulvestrant

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.